Skip to main content
JIUZHITANG CO.,LTD logo

JIUZHITANG CO.,LTD — Investor Relations & Filings

Ticker · 000989 ISIN · CNE000001394 LEI · 3003004OFW6FCZ34KN72 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,885 across all filing types
Latest filing 2024-01-24 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000989

About JIUZHITANG CO.,LTD

https://www.hnjzt.com

JIUZHITANG CO.,LTD. is a pharmaceutical enterprise specializing in the research, development, manufacturing, and distribution of Traditional Chinese Medicine (TCM). Established in 1650, the company is recognized as a time-honored brand with a heritage spanning over three centuries. Its core product portfolio includes a diverse range of TCM formulations, most notably Liuwei Dihuang Wan, donkey-hide gelatin (Ejiao), and various health supplements focused on chronic disease management and general wellness. The company operates modern production facilities that integrate traditional processing techniques with contemporary scientific standards and biotechnology. JIUZHITANG focuses on the modernization of TCM through clinical research and innovation, maintaining a distribution network that serves retail pharmacies and medical institutions to provide natural healthcare solutions.

Recent filings

Filing Released Lang Actions
关于控股股东部分股份质押的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the pledge of shares by a controlling shareholder, including detailed tables of pledged shares, pledge terms, and risk disclosures. It does not contain financial statements, earnings data, or management discussion of results. It is a regulatory disclosure about share pledge status, which fits the category of a Regulatory Filing (RNS) as it is a compliance announcement about share pledges and related risks, not a financial report or capital raising update.
2024-01-24 Chinese
关于公司董事会、监事会延期换届选举的公告
Board/Management Information Classification · 100% confidence The document is an announcement from the company 九芝堂股份有限公司 regarding the postponement of the board of directors and supervisory board re-election. It discusses the extension of the current board's term and the continuation of duties until the new board is elected. There is no financial data, no report attached or referenced as being published, and no mention of financial results or regulatory certifications. The content is about management and board changes, specifically the delay in board elections. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on this announcement, confirming it is not a full report or other filing type.
2023-12-22 Chinese
关于主要产品疏血通注射液在2023年国家医保目录中解除部分限制的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1257 characters) from 九芝堂股份有限公司 regarding changes in the 2023 National Medical Insurance Directory affecting the restrictions on one of its main products. It provides details about the product, sales figures, and the expected impact of the policy change. There is no detailed financial report or comprehensive data, nor is it a transcript, audit, or management report. The document is an official announcement about regulatory changes impacting the company’s product sales and includes a risk warning to investors. It does not contain financial statements or detailed analysis, so it is not an Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it contains substantive content about the policy change and its impact. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-12-13 Chinese
关于持股5%以上股东减持计划期限届满暨实施结果的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the completion of a shareholding reduction plan by a shareholder holding more than 5% of the company's shares. It details the number of shares reduced, the period, the method, and the impact on shareholding percentages. It includes specific data about the shareholder's holdings before and after the reduction and confirms compliance with relevant regulations. This type of document fits the definition of a Major Shareholding Notification (MRQ), as it reports changes in significant share ownership levels crossing thresholds. The document is not a full financial report, earnings release, or management report, nor is it a proxy or voting result announcement. It is a regulatory disclosure about shareholding changes by a major shareholder.
2023-12-13 Chinese
关于全资子公司研发新药启动临床试验的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1350 characters) titled as a "临时公告" (temporary announcement) from 九芝堂股份有限公司 regarding the start of clinical trials by its wholly-owned subsidiary. It describes the clinical trial project, its approval, and potential impact on the company. There are no financial statements, no detailed financial data, or comprehensive report content. The document is an announcement of a corporate event related to R&D progress, not a financial report or regulatory filing of financial results. It is not a report publication announcement since it does not mention any report being published or attached. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a material event that does not fit other specific categories.
2023-12-13 Chinese
关于子公司药品研发启动临床试验的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1437 characters) from 九芝堂股份有限公司 about the initiation of clinical trials by its subsidiary. It details the clinical trial project, regulatory approvals, and potential impacts on the company. There are no financial statements, no detailed financial data, or comprehensive report content. The document is an announcement of a specific event related to the company's operations and regulatory approvals, not a full report or financial filing. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is also not a regulatory certification or insider dealing report. Given the nature and length, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2023-11-01 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.